PharmaJet Received Multi-Year, Multi-Million Dollar Award to Support Next-Generation Needle-free Delivery Devices

GOLDEN, Colo. — March 17, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA). DTRA, through the Medical CBRN Defense Consortium (MCDC), is funding the use of needle-free technology to further progress promising nucleic acid vaccines, while also funding the development of PharmaJet’s next generation needle-free devices.

First large-scale polio vaccination campaign using PharmaJet intradermal Needle-free Injector

GOLDEN, Colo. — February 5, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the publication of independent survey results from the first large-scale campaign using its needle-free technology. The paper, entitled Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, was published in Vaccine on January 23, 2020.

Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector

GOLDEN, Colo. — January 8, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that the results of the Invectys Phase I clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system, were recently published. The study entitled A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors was published in Clinical Cancer Research on November 19, 2019.

PharmaJet Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors

GOLDEN, Colo. — December 17, 2019 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Kevin L. Lorenz, J.D., has been appointed to its Board of Directors. Mr. Lorenz, Chief Investment Officer, Senior Vice President, Treasury and Private Investments at the Katz Group, is an accomplished executive with over 25 years of experience guiding and implementing investment strategy across public and private companies.

PharmaJet presents latest Research Results at World Vaccine Congress

GOLDEN, Colo. — May 7, 2019 — PharmaJet®, the maker of innovative, needle-free injection technology, today shared that their latest research results were presented at the World Vaccine Congress on April 16, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effective-ness with Needle-free Delivery, was presented by Dr. Marilyn Dysart, Clinical Affairs Manager at PharmaJet, Inc.

PharmaJet to present latest Research Results at World Vaccine & Immunotherapy Congress

GOLDEN, Colo. — November 27, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced plans to present their latest re-search results at the World Vaccine & Immunotherapy Congress on November 29 at the Loews Coronado Bay Resort in San Diego, California. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.

PharmaJet and Mundipharma partner to expand access to needle-free technology in emerging markets

SINGAPORE — July 25, 2018 — PharmaJet® the maker of innovative, needle-free injection technology, and Mundipharma, today announced an exclusive partnership for the multinational healthcare organization to market and distribute PharmaJet's Tropis® and Stratis® needle-free devices across more than 120 markets worldwide. Tropis® (ID) and Stratis® (IM/SC) devices are both optimized for vaccine immunizations.

PharmaJet to present latest Research Results at World Vaccine Congress

GOLDEN, Colo. — March 27, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced plans to present their latest research results at the World Vaccine Congress on April 5, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.

Phase 1 clinical trial for Hantavirus vaccines yields positive interim results

GOLDEN, Colo. — March 13, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the reporting of positive interim results from the Phase 1 clinical trial conducted by the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The clinical trial is evaluating two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS), using the PharmaJet Stratis® needle-free injection system.